These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29253435)

  • 1. Legalisation of non-medical cannabis in Canada: will supply regulations effectively serve public health?
    Fischer B
    Lancet Public Health; 2017 Dec; 2(12):e536-e537. PubMed ID: 29253435
    [No Abstract]   [Full Text] [Related]  

  • 2. Facing the option for the legalisation of cannabis use and supply in New Zealand: An overview of relevant evidence, concepts and considerations.
    Fischer B; Daldegan-Bueno D; Boden JM
    Drug Alcohol Rev; 2020 Jul; 39(5):555-567. PubMed ID: 32436274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Zealand's 'Cannabis Legalisation and Regulation Bill': an evidence-based assessment and critique of essential regulatory components towards policy outcomes.
    Fischer B; Daldegan-Bueno D
    N Z Med J; 2020 Jul; 133(1519):103-111. PubMed ID: 32777801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Le marché légal du cannabis suite à sa légalisation au Canada : pistes de réflexion pour un encadrement efficace.
    Patenaude C; Brochu S; Fallu JS; Jutras-Aswad D; D'Arcy L
    Can J Public Health; 2018 Apr; 109(2):215-218. PubMed ID: 29981041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in health harms due to cannabis following legalisation of non-medical cannabis in Canada in context of cannabis commercialisation: A scoping review.
    Myran DT; Imtiaz S; Konikoff L; Douglas L; Elton-Marshall T
    Drug Alcohol Rev; 2023 Feb; 42(2):277-298. PubMed ID: 36165188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to legal cannabis market in Canada over the four years following non-medical cannabis legalisation.
    Myran DT; Friesen EL; Dickson S; Konikoff L; Arora G; Tanuseputro P
    Drug Alcohol Rev; 2023 Jul; 42(5):1114-1119. PubMed ID: 36933893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social and public health implications of the legalisation of recreational cannabis: A literature review.
    Mokwena K
    Afr J Prim Health Care Fam Med; 2019 Nov; 11(1):e1-e6. PubMed ID: 31793317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A common public health-oriented policy framework for cannabis, alcohol and tobacco in Canada?
    Kirst M; Kolar K; Chaiton M; Schwartz R; Emerson B; Hyshka E; Jesseman R; Lucas P; Solomon R; Thomas G
    Can J Public Health; 2016 Mar; 106(8):e474-6. PubMed ID: 26986906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for public health and safety metrics to evaluate the potential harms and benefits of cannabis regulation in Canada.
    Lake S; Kerr T; Werb D; Haines-Saah R; Fischer B; Thomas G; Walsh Z; Ware MA; Wood E; Milloy MJ
    Drug Alcohol Rev; 2019 Sep; 38(6):606-621. PubMed ID: 31577059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of "home" cultivation policies and the case for community-based cannabis supply.
    Belackova V; Roubalova Stefunkova M; van de Ven K
    Int J Drug Policy; 2019 Sep; 71():36-46. PubMed ID: 31200326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA.
    Chiu V; Leung J; Hall W; Stjepanović D; Degenhardt L
    Neuropharmacology; 2021 Aug; 193():108610. PubMed ID: 34010617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moral regulation and the presumption of guilt in Health Canada's medical cannabis policy and practice.
    Lucas P
    Int J Drug Policy; 2009 Jul; 20(4):296-303. PubMed ID: 19124233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debate over recreational cannabis use legalisation in Canada.
    Webster P
    Lancet; 2018 Feb; 391(10122):725-726. PubMed ID: 29486935
    [No Abstract]   [Full Text] [Related]  

  • 14. A missed opportunity? Cannabis legalization and reparations in Canada.
    Valleriani J; Lavalley J; McNeil R
    Can J Public Health; 2018 Dec; 109(5-6):745-747. PubMed ID: 30225575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging prospects for non-medical cannabis legalisation in New Zealand: An initial view and contextualization.
    Fischer B; Bullen C
    Int J Drug Policy; 2020 Feb; 76():102632. PubMed ID: 31864106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-medical cannabis in North America: an overview of regulatory approaches.
    Lancione S; Wade K; Windle SB; Filion KB; Thombs BD; Eisenberg MJ
    Public Health; 2020 Jan; 178():7-14. PubMed ID: 31600630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabis legalisation in Canada: a crucial trial balloon.
    Hill KP; George TP
    Lancet Psychiatry; 2019 Jan; 6(1):5-6. PubMed ID: 30579495
    [No Abstract]   [Full Text] [Related]  

  • 18. Recreational cannabis legalisation: details will determine mental health effects.
    Hill KP
    Lancet Psychiatry; 2016 Sep; 3(9):798-9. PubMed ID: 27374073
    [No Abstract]   [Full Text] [Related]  

  • 19. How has access to legal cannabis changed over time? An analysis of the cannabis retail market in Canada 2 years following the legalisation of recreational cannabis.
    Myran DT; Staykov E; Cantor N; Taljaard M; Quach BI; Hawken S; Tanuseputro P
    Drug Alcohol Rev; 2022 Feb; 41(2):377-385. PubMed ID: 34250645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis policy in The Netherlands: Rationale and design of an experiment with a controlled legal ('closed') cannabis supply chain.
    Knottnerus JA; Blom T; van Eerden S; Mans JHH; Mheen DV; de Neeling JND; Schelfhout DCL; Seidell JC; van Wijk AH; van Wingerde CGK; Brink WVD
    Health Policy; 2023 Mar; 129():104699. PubMed ID: 36566153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.